Summary of Sera Prognostics Q1 2026 Earnings Call

1Key Financial Results and Metrics

Revenue: $14,000 for Q1 2026, down from $38,000 in Q1 2025, reflecting the ongoing transition in commercialization strategy.

Operating Expenses: $9.4 million, slightly up from $9.3 million in the previous year, attributed to continued investments in advocacy and regulatory preparation.

Net Loss: $8.4 million, compared to a net loss of $8.2 million in Q1 2025.

Cash Position: $86.8 million in cash and equivalents, sufficient to fund operations through 2029 due to a strategic shift in spending towards commercialization.

2Strategic Updates and Business Highlights

Focus on building awareness and access for the PreTRM test, particularly following the PRIME study results.

Launched a third partnership program aimed at reaching over 350 providers across three states, enhancing clinical footprint and risk identification for preterm births.

Engaged with 13 payers across 15 states to deepen relationships and facilitate reimbursement strategies.

Continued advocacy efforts, including a letter-writing campaign to encourage Medicaid coverage for the PreTRM test.

Progress towards commercialization in Europe, with plans for CE Marking submission mid-year.

3Forward Guidance and Outlook

Revenue in 2026 expected to remain modest and uneven as the company pushes for reimbursement and awareness.

Anticipation of increased adoption and revenue pull-through later in 2026 and into 2027.

The company is on track to publish several PRIME sub-analyses throughout 2026, which are expected to strengthen the clinical and economic foundation for PreTRM adoption.

4Bad News, Challenges, or Points of Concern

Revenue decline indicates challenges in achieving immediate commercial traction despite strategic initiatives.

The modest revenue reflects the timing of the commercialization strategy and the need for continued advocacy and awareness-building efforts.

The transition to a more commercial focus may lead to reduced R&D capacity, which could impact future product development and innovation.

Potential delays in Medicaid coverage decisions for the PreTRM test could hinder broader adoption.

5Notable Q&A Insights

The company plans to launch one partner program per quarter, emphasizing the importance of thorough integration with providers and payers.

Metrics related to sales rep productivity are being monitored internally, with plans to report them once steady progress is observed.

The timeline for Medicaid coverage decisions is estimated to be around two years, with the possibility of delays depending on data collection and analysis complexities.

The shift in resources from R&D to commercial efforts was driven by reduced internal demand and external interest in collaborative R&D partnerships. Overall, Sera Prognostics is focusing on building a solid foundation for the PreTRM test's adoption while navigating the challenges of commercialization and reimbursement in a competitive healthcare landscape.